文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

乳糜泻中麸质介导的细胞因子释放期间血清细胞因子升高。

Serum cytokines elevated during gluten-mediated cytokine release in coeliac disease.

机构信息

ImmusanT, Inc., Cambridge, MA,, USA.

Faculty of Medicine, University of Queensland, 288 Herston Rd, Herston, 4006, QLD, Australia.

出版信息

Clin Exp Immunol. 2020 Jan;199(1):68-78. doi: 10.1111/cei.13369. Epub 2019 Oct 1.


DOI:10.1111/cei.13369
PMID:31505020
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6904604/
Abstract

Cytokines have been extensively studied in coeliac disease, but cytokine release related to exposure to gluten and associated symptoms has only recently been described. Prominent, early elevations in serum interleukin (IL)-2 after gluten support a central role for T cell activation in the clinical reactions to gluten in coeliac disease. The aim of this study was to establish a quantitative hierarchy of serum cytokines and their relation to symptoms in patients with coeliac disease during gluten-mediated cytokine release reactions. Sera were analyzed from coeliac disease patients on a gluten free-diet (n = 25) and from a parallel cohort of healthy volunteers (n = 25) who underwent an unmasked gluten challenge. Sera were collected at baseline and 2, 4 and 6 h after consuming 10 g vital wheat gluten flour; 187 cytokines were assessed. Confirmatory analyses were performed by high-sensitivity electrochemiluminescence immunoassay. Cytokine elevations were correlated with symptoms. Cytokine release following gluten challenge in coeliac disease patients included significant elevations of IL-2, chemokine (C-C motif) ligand 20 (CCL20), IL-6, chemokine (C-X-C motif) ligand (CXCL)9, CXCL8, interferon (IFN)-γ, IL-10, IL-22, IL-17A, tumour necrosis factor (TNF)-α, CCL2 and amphiregulin. IL-2 and IL-17A were earliest to rise. Peak levels of cytokines were generally at 4 h. IL-2 increased most (median 57-fold), then CCL20 (median 10-fold). Cytokine changes were strongly correlated with one another, and the most severely symptomatic patients had the highest elevations. Early elevations of IL-2, IL-17A, IL-22 and IFN-γ after gluten in patients with coeliac disease implicates rapidly activated T cells as their probable source. Cytokine release after gluten could aid in monitoring experimental treatments and support diagnosis.

摘要

细胞因子在乳糜泻中得到了广泛的研究,但与接触麸质和相关症状相关的细胞因子释放最近才被描述。在乳糜泻中,麸质支持 T 细胞激活在对麸质的临床反应中起核心作用,这一观点得到了血清白细胞介素 (IL)-2 早期升高的支持。本研究的目的是在乳糜泻患者的麸质介导的细胞因子释放反应中,建立一个血清细胞因子的定量层次及其与症状的关系。在无麸质饮食(n=25)和来自平行队列的健康志愿者(n=25)中分析乳糜泻患者的血清,这些志愿者接受了未掩盖的麸质挑战。在摄入 10 克活力小麦麸质面粉后 2、4 和 6 小时采集血清;评估了 187 种细胞因子。通过高灵敏度电化学发光免疫分析法进行确认分析。细胞因子升高与症状相关。乳糜泻患者麸质挑战后的细胞因子释放包括白细胞介素-2(IL-2)、趋化因子(C-C 基序)配体 20(CCL20)、白细胞介素-6(IL-6)、趋化因子(C-X-C 基序)配体(CXCL)9、CXCL8、干扰素(IFN)-γ、白细胞介素-10(IL-10)、白细胞介素-22(IL-22)、白细胞介素-17A(IL-17A)、肿瘤坏死因子(TNF)-α、CCL2 和 Amphiregulin 的显著升高。IL-2 和 IL-17A 最早升高。细胞因子的峰值水平通常在 4 小时。IL-2 增加最多(中位数 57 倍),其次是 CCL20(中位数 10 倍)。细胞因子变化彼此之间强烈相关,症状最严重的患者升高幅度最大。乳糜泻患者麸质后早期升高的白细胞介素-2、白细胞介素-17A、白细胞介素-22 和干扰素-γ提示迅速激活的 T 细胞可能是其来源。麸质后细胞因子的释放可能有助于监测实验性治疗并支持诊断。

相似文献

[1]
Serum cytokines elevated during gluten-mediated cytokine release in coeliac disease.

Clin Exp Immunol. 2019-10-1

[2]
Whole blood interleukin-2 release test to detect and characterize rare circulating gluten-specific T cell responses in coeliac disease.

Clin Exp Immunol. 2021-6

[3]
A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease.

Front Immunol. 2021

[4]
Cytokine release after gluten ingestion differentiates coeliac disease from self-reported gluten sensitivity.

United European Gastroenterol J. 2020-2

[5]
Increased proinflammatory cytokine gene expression in the colonic mucosa of coeliac disease patients in the early period after gluten challenge.

Clin Exp Immunol. 1997-1

[6]
Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease.

BMC Med. 2020-11-26

[7]
Elevated serum interleukin-2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease.

Aliment Pharmacol Ther. 2019-9-4

[8]
Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma.

Gut. 1995-12

[9]
Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease.

Gastroenterology. 1998-9

[10]
Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease.

Sci Adv. 2019-8-7

引用本文的文献

[1]
Gastrointestinal and Extraintestinal Symptoms Among Subjects With Celiac Disease Undergoing a Dose-Specified Gluten Challenge: A Systematic Review and Meta-Analysis.

Am J Gastroenterol. 2025-4-29

[2]
Diagnosis of celiac disease on a gluten-free diet: a multicenter prospective quasi-experimental clinical study.

BMC Med. 2025-3-26

[3]
Celiac Disease and Gluten Cross-Contact: How Much is too Much?

Curr Nutr Rep. 2025-3-5

[4]
Review Article: Novel Enzyme Therapy Design for Gluten Peptide Digestion Through Exopeptidase Supplementation.

Aliment Pharmacol Ther. 2025-4

[5]
InTiCAR: Network-based identification of significant inter-tissue communicators for autoimmune diseases.

Comput Struct Biotechnol J. 2025-1-10

[6]
Circulating MicroRNAs and Cytokines Associated with Celiac Disease.

Middle East J Dig Dis. 2024-7

[7]
The role of IL-37 in gastrointestinal diseases.

Front Immunol. 2024

[8]
The Role of Viruses in the Pathogenesis of Immune-Mediated Gastro-Intestinal Diseases.

Int J Mol Sci. 2024-7-30

[9]
A human autoimmune organoid model reveals IL-7 function in coeliac disease.

Nature. 2024-8

[10]
Global Approach to Follow-Up of Celiac Disease.

Foods. 2024-5-8

本文引用的文献

[1]
Elevated serum interleukin-2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease.

Aliment Pharmacol Ther. 2019-9-4

[2]
Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease.

Sci Adv. 2019-8-7

[3]
Randomised clinical trial: a placebo-controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease.

Aliment Pharmacol Ther. 2019-8-13

[4]
Evolving Therapy for Celiac Disease.

Front Pediatr. 2019-5-14

[5]
Plasma Cells Are the Most Abundant Gluten Peptide MHC-expressing Cells in Inflamed Intestinal Tissues From Patients With Celiac Disease.

Gastroenterology. 2018-12-26

[6]
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Biol Blood Marrow Transplant. 2018-12-25

[7]
Meta-analysis of Immunochip data of four autoimmune diseases reveals novel single-disease and cross-phenotype associations.

Genome Med. 2018-12-20

[8]
Analysis of IL17A and IL21 Expression in the Small Intestine of Celiac Disease Patients and Correlation with Circulating Thioredoxin Level.

Genet Test Mol Biomarkers. 2018-9

[9]
Outcome measures in coeliac disease trials: the Tampere recommendations.

Gut. 2018-2-13

[10]
HLA-DQ-Gluten Tetramer Blood Test Accurately Identifies Patients With and Without Celiac Disease in Absence of Gluten Consumption.

Gastroenterology. 2017-11-14

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索